skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Brivanib Alaninate (Code C53397)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Brivanib Alaninate

Definition: The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression.

NCI-GLOSS Definition: A substance being studied in the treatment of cancer. Brivanib alaninate may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor 2 inhibitor and a type of antiangiogenesis agent.

Display Name: Brivanib Alaninate

Label: Brivanib Alaninate

NCI Thesaurus Code: C53397 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1701190  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
BMS 582664
Brivanib Alaninate
brivanib alaninate

External Source Codes: 
CAS Registry Number 649735-63-7 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 462556
PDQ Open Trial Search ID 462556 (check for NCI PDQ open clinical trial info)
UMLS CUI C1701190

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C22H24FN5O4
code C53397
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name BMS-582664
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom